Charles River Laboratories International, Inc. (NYSE: CRL) today
reported its results for the second quarter of 2010. For the
quarter, net sales were $292.1 million, a decline of 5.2% from
$308.2 million in the second quarter of 2009. Foreign currency
translation reduced the sales growth rate by 0.1%. A modest sales
increase in the Research Models and Services (RMS) segment was
offset by lower sales for the Preclinical Services (PCS)
segment.
On a GAAP basis, net income attributable to common shareholders
for the second quarter of 2010 was $14.5 million, or $0.22 per
diluted share, compared to net income of $34.2 million, or $0.52
per diluted share, for the second quarter of 2009.
On a non-GAAP basis, net income was $32.1 million for the second
quarter of 2010, compared to $43.1 million for the same period in
2009, a decrease of 25.5%. Second-quarter diluted earnings per
share on a non-GAAP basis were $0.49, a decrease of 25.8% compared
to $0.66 per share in the second quarter of 2009. Both the GAAP and
non-GAAP results were impacted by lower sales volume and higher
costs related to the Company’s enterprise resource planning (ERP)
initiative, offset in part by cost-savings actions implemented
throughout 2009 and in the first quarter of 2010.
James C. Foster, Chairman, President and Chief Executive
Officer, said, “We are disappointed that market demand for
outsourced preclinical services did not rebound during the second
quarter as we had previously expected. We continue to have
extensive discussions with our biopharmaceutical clients, who
maintain their intentions to build larger, strategic partnerships
with us and increase the amount of outsourced activity. However,
the timing of these decisions remains unclear and we do not believe
that it is imminent. While our results provide reassurance that
preclinical demand appears to have stabilized, positive indications
such as the increased number of inquiries and improved June
bookings are offset by their value, which is lower due to pricing.
Therefore, we now expect PCS sales to be flat sequentially for the
remainder of the year, and have tempered our RMS outlook to reflect
lower sales of research models associated with preclinical studies.
As a result, we have lowered our sales and EPS guidance for
2010.”
Second-Quarter Segment
Results
Research Models and Services (RMS)
Sales for the RMS segment were $167.1 million in the second
quarter of 2010, an increase of 0.9% from $165.7 million in the
second quarter of 2009. Foreign currency translation reduced the
sales growth rate by 1.0%. Excluding the effect of foreign
exchange, RMS sales improved by 1.9% as strong growth of In Vitro
products and contributions from the Piedmont and Cerebricon
acquisitions (May and August 2009, respectively) were partially
offset by lower sales of large models. The sequential decline in
RMS sales from the first quarter of 2010 was driven primarily by
foreign exchange, particularly the weakening of the Euro, as well
as the large models business.
In the second quarter of 2010, the RMS segment’s GAAP operating
margin was 28.3% compared to 30.7% for the second quarter of 2009.
On a non-GAAP basis, the operating margin decreased to 29.1% from
31.9% in the second quarter of 2009. The margin decline was
primarily attributable to lower sales volume of large models, as
well as higher information technology and compensation costs.
Preclinical Services (PCS)
Second-quarter 2010 net sales for the PCS segment were $125.0
million, a decrease of 12.3% from $142.5 million in the second
quarter of 2009. The PCS sales decline was due primarily to
continued measured demand for our services from large
pharmaceutical and biotechnology companies, as well as stable but
lower than historical prices. Significantly lower sales of our
clinical Phase I services also contributed. The sales decline was
partially offset by the positive effect of foreign currency
translation, which increased the growth rate by 0.8%.
A greater proportion of short-term, less complex studies in the
sales mix, lower sales of clinical Phase I services and the
continued impact of lower prices, partially offset by cost-saving
actions, resulted in lower operating margins for the PCS segment.
The second-quarter 2010 GAAP operating margin declined to 3.8% from
11.5% in the second quarter of 2009. On a non-GAAP basis, the
operating margin declined to 12.0% from 17.2% in the second quarter
of 2009. The PCS operating margin did improve sequentially by 270
basis points on a non-GAAP basis and 400 basis points on a GAAP
basis when compared to the first quarter of 2010, driven primarily
by the Company’s plan to suspend operations at its PCS
Massachusetts facility and transition clients to other sites within
the global PCS network.
Six-Month
Results
For the first six months of 2010, net sales decreased by 3.3% to
$589.4 million from $609.7 million in the same period in 2009.
Foreign currency translation benefited net sales growth by
1.6%.
On a GAAP basis, net income attributable to common shareholders
was $31.8 million, or $0.48 per diluted share, for the first half
of 2010, compared to $59.6 million, or $0.91 per diluted share, for
the same period in 2009.
On a non-GAAP basis, net income for the first six months of 2010
was $61.5 million, or $0.93 per diluted share, compared to $81.3
million, or $1.24 per diluted share, for the same period in
2009.
Research Models and Services (RMS)
For the first six months of 2010, RMS net sales were $339.3
million, an increase of 3.7% from first-half 2009 net sales of
$327.2 million, with foreign currency translation contributing 1.0%
to the increase. The RMS segment’s GAAP operating margin was 28.7%
in the first half of 2010, compared to 30.1% for the prior-year
period. On a non-GAAP basis, the operating margin was 29.8%
compared to 31.7% in the first six months of 2009.
Preclinical Services (PCS)
For the first six months of 2010, PCS net sales were $250.1
million, a decrease of 11.5% from first-half 2009 net sales of
$282.5 million. Foreign currency translation benefited net sales
growth by 2.4%. On a GAAP basis, the PCS segment operating margin
was 1.8% in the first half of 2010, compared to 9.5% in the
prior-year period. On a non-GAAP basis, the operating margin was
10.7% in the first half of 2010 compared to 16.4% for the same
period in 2009.
Items Excluded from Non-GAAP
Results
Items excluded from non-GAAP results in the second quarter of
2010 and 2009 were as follows:
($ in millions) 2Q10
2Q09 Amortization of intangible assets
$ 6.0 $ 7.2 Severance related to
cost-saving actions 2.1
1.7 Impairment and other charges (1)
0.0 0.2
Operating losses for PCS
Massachusetts, PCS Arkansas andclinical Phase I Scotland
3.5 1.1
Costs associated with evaluation of acquisitions
8.3 0.4 Convertible debt
accounting 3.2
2.7 Tax expense from cash repatriation
2.7 --
(1) In the second quarter of 2009, these items were related
primarily to costs associated with the Company’s divestiture of its
clinical Phase I business in Scotland on May 15, 2009.
Items excluded from non-GAAP results in the first half of 2010
and 2009 are as follows:
($ in millions) 1H10
1H09 Amortization of intangible assets
$ 13.2 $ 13.4 Severance related
to cost-saving actions 4.8
8.8 Impairment and other charges (1)
0.9 1.8
Operating losses for PCS
Massachusetts, PCS Arkansas andclinical Phase I Scotland
7.0 2.7
Costs associated with evaluation of acquisitions
8.4 0.6 Convertible debt
accounting 6.3
5.1 Tax expense from cash repatriation
2.7 --
(1) In the first half of 2010, these items were related
primarily to an asset impairment associated with the Company’s
planned disposition of its PCS facility in Arkansas. In the first
half of 2009, these items were related primarily to an asset
impairment charge and costs associated with the Company’s
divestiture of its clinical Phase I business in Scotland and
additional miscellaneous expenses.
2010 Guidance
The Company is reducing its forward-looking guidance for 2010,
which was originally provided on February 8, 2010. This guidance
now assumes that PCS sales in the second half of 2010 will remain
flat when compared to the first half of the year. RMS sales for the
remaining two quarters of the year are expected to decline
moderately from the second-quarter 2010 level, due largely to
continued softness in demand for research models used in toxicology
and normal seasonality. For the full year, RMS sales are expected
to remain flat to slightly above the 2009 level. The sales guidance
has also been updated to reflect negative movements in foreign
currency translation, which is now expected to reduce sales growth
by approximately 1.0% compared to 2009.
2010 GUIDANCE REVISED
PRIOR Net sales 2%-3% decrease
Low single-digitgrowth
GAAP EPS estimate $ 0.71 - $0.81 $ 1.57
- $1.77 Amortization of intangible assets $ 0.27
$ 0.30
Severance costs and operating
losses primarilyattributable to suspension of PCS
Massachusettsoperations
$ 0.16 $ 0.20 Impairment and other
charges (1) $ 0.01 -- Costs
associated with the evaluation of acquisitions (2) $
0.58 -- Convertible debt accounting
$ 0.13 $ 0.13 Tax expense from cash
repatriation $ 0.04 -- Non-GAAP
EPS estimate $ 1.90 - $2.00 $ 2.20 -
$2.40
(1) These items are primarily related to an asset impairment in
the first half of 2010 associated with the Company’s planned
disposition of its PCS facility in Arkansas.
(2) This item is an estimate of the advisory fees, breakup fee
and related deal costs primarily associated with the proposed
acquisition of WuXi PharmaTech (Cayman) Inc.
Webcast
Rescheduled
Charles River Laboratories has rescheduled its live webcast to
Monday, August 2, at 8:30 a.m. ET to discuss matters relating to
this press release. To participate, please go to ir.criver.com and
select the webcast link. You can also find the associated slide
presentation and reconciliations of non-GAAP financial measures to
comparable GAAP financial measures on the website.
Use of Non-GAAP Financial
Measures
This press release contains non-GAAP financial measures, such as
non-GAAP earnings per diluted share, which exclude amortization of
intangible assets and other charges related to our acquisitions,
expenses associated with evaluating acquisitions (including costs
related to the termination of the proposed acquisition of WuXi),
charges and operating losses attributable to our businesses we plan
to close or divest, severance costs associated with our 2009 and
2010 cost-saving actions, tax expense associated with the
repatriation of cash into the United States, and the additional
interest recorded as a result of the adoption in 2009 of an
accounting standard related to our convertible debt accounting
which increased interest and depreciation expense. We exclude these
items from the non-GAAP financial measures because they are outside
our normal operations. There are limitations in using non-GAAP
financial measures, as they are not prepared in accordance with
generally accepted accounting principles, and may be different than
non-GAAP financial measures used by other companies. In particular,
we believe that the inclusion of supplementary non-GAAP financial
measures in this press release helps investors to gain a meaningful
understanding of our core operating results and future prospects
without the effect of these often-one-time charges, and is
consistent with how management measures and forecasts the Company's
performance, especially when comparing such results to prior
periods or forecasts. We believe that the financial impact of our
acquisitions (and in certain cases, the evaluation of such
acquisitions, whether or not ultimately consummated) is often large
relative to our overall financial performance, which can adversely
affect the comparability of our results on a period-to-period
basis. In addition, certain activities, such as business
acquisitions, happen infrequently and the underlying costs
associated with such activities do not recur on a regular basis.
Non-GAAP results also allow investors to compare the Company’s
operations against the financial results of other companies in the
industry who similarly provide non-GAAP results. The non-GAAP
financial measures included in this press release are not meant to
be considered superior to or a substitute for results of operations
prepared in accordance with GAAP. The Company intends to continue
to assess the potential value of reporting non-GAAP results
consistent with applicable rules and regulations. Reconciliations
of the non-GAAP financial measures used in this press release to
the most directly comparable GAAP financial measures are set forth
in the text of this press release, and can also be found on the
Company’s website at ir.criver.com.
Caution Concerning
Forward-Looking Statements
This news release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words
such as “anticipate,” “believe,” “expect,” “will,” “may,”
“estimate,” “plan,” “outlook,” and “project” and other similar
expressions that predict or indicate future events or trends or
that are not statements of historical matters. These statements
also include statements regarding our projected 2010 financial
performance including sales and earnings; the future demand for
drug discovery and development products and services (particularly
in light of the challenging economic environment), our expectations
regarding stock repurchases; the development and performance of our
services and products; market and industry conditions including the
outsourcing of these services and present spending trends by our
customers; and Charles River’s future performance as delineated in
our forward-looking guidance, and particularly our expectations
with respect to sales and foreign exchange impact. Forward-looking
statements are based on Charles River’s current expectations and
beliefs, and involve a number of risks and uncertainties that are
difficult to predict and that could cause actual results to differ
materially from those stated or implied by the forward-looking
statements. Those risks and uncertainties include, but are not
limited to: the ability to successfully integrate businesses we
acquire; negative trends in research and development spending,
negative trends in the level of outsourced services, or other cost
reduction actions by our customers; the ability to convert backlog
to sales; special interest groups; contaminations; industry trends;
new displacement technologies; USDA and FDA regulations; changes in
law; continued availability of products and supplies; loss of key
personnel; interest rate and foreign currency exchange rate
fluctuations; changes in tax regulation and laws; changes in
generally accepted accounting principles; and any changes in
business, political, or economic conditions due to the threat of
future terrorist activity in the U.S. and other parts of the world,
and related U.S. military action overseas. A further description of
these risks, uncertainties, and other matters can be found in the
Risk Factors detailed in Charles River's Annual Report on Form 10-K
as filed on February 19, 2010, as well as other filings we make
with the Securities and Exchange Commission. Because
forward-looking statements involve risks and uncertainties, actual
results and events may differ materially from results and events
currently expected by Charles River, and Charles River assumes no
obligation and expressly disclaims any duty to update information
contained in this news release except as required by law.
About Charles River
Accelerating Drug Development. Exactly. Charles River provides
essential products and services to help pharmaceutical and
biotechnology companies, government agencies and leading academic
institutions around the globe accelerate their research and drug
development efforts. Our approximately 8,000 employees worldwide
are focused on providing clients with exactly what they need to
improve and expedite the discovery, development through
first-in-human evaluation, and safe manufacture of new therapies
for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CONDENSED
CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (dollars in
thousands, except for per share data)
Three Months Ended
Six Months Ended
June 26,2010
June 27,2009
June 26,2010
June 27,2009
Total net sales $ 292,104 $ 308,159 $ 589,449 $ 609,685 Cost
of products sold and services provided
191,740
193,696
389,168 387,002
Gross margin 100,364 114,463 200,281 222,683 Selling, general and
administrative 66,127 56,582 129,368 118,760 Amortization of
intangibles
6,033
7,219 13,207
13,368 Operating income 28,204 50,662 57,706
90,555 Interest income (expense) (6,843 ) (4,942 ) (12,453 ) (9,546
) Other income (expense)
(736 )
1,565 (1,147
) 1,303 Income before
income taxes 20,625 47,285 44,106 82,312 Provision for income taxes
6,530 13,630
13,011 23,788
Net income 14,095 33,655 31,095 58,524 Noncontrolling interests
359 499
741 1,035 Net
income attributable to common shareowners
$
14,454 $ 34,154
$ 31,836 $
59,559 Earnings per common share Basic $
0.22 $ 0.53 $ 0.49 $ 0.91 Diluted $ 0.22 $ 0.52 $ 0.48 $ 0.91
Weighted average number of common shares outstanding Basic
65,289,617 65,046,023 65,381,634 65,467,929 Diluted 65,874,284
65,222,498 66,017,118 65,615,498
CHARLES RIVER LABORATORIES
INTERNATIONAL, INC. CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED) (dollars in thousands)
June 26,2010
December 26,2009
Assets Current assets Cash and cash equivalents $ 219,077 $
182,574 Trade receivables, net 218,695 196,947 Inventories 96,571
102,723 Other current assets
73,705
113,357 Total current assets 608,048 595,601 Property,
plant and equipment, net 837,580 865,743 Goodwill, net 500,585
508,235 Other intangibles, net 144,025 160,292 Deferred tax asset
12,926 18,978 Other assets
53,473
55,244 Total assets
$
2,156,637 $ 2,204,093
Liabilities and Equity Current liabilities Current portion
of long-term debt & capital leases $ 26,774 $ 35,413 Accounts
payable 29,681 31,232 Accrued compensation 49,215 45,522 Deferred
revenue 61,651 72,390 Accrued liabilities 59,570 49,997 Other
current liabilities
19,169
15,219 Total current liabilities 246,060 249,773
Long-term debt & capital leases 409,441 457,419 Other long-term
liabilities
107,119 123,077
Total liabilities
762,620
830,269 Total equity
1,394,017
1,373,824 Total liabilities and equity
$ 2,156,637 $
2,204,093 CHARLES RIVER LABORATORIES INTERNATIONAL,
INC. SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)
(dollars in thousands)
Three Months Ended
Six Months Ended
June 26,2010
June 27,2009
June 26,2010
June 27,2009
Research Models and Services Net sales $ 167,140 $ 165,682 $
339,345 $ 327,172 Gross margin 71,346 71,206 145,625 139,519 Gross
margin as a % of net sales 42.7 % 43.0 % 42.9 % 42.6 % Operating
income 47,258 50,894 97,242 98,338 Operating income as a % of net
sales 28.3 % 30.7 % 28.7 % 30.1 % Depreciation and amortization
8,811 8,049 18,532 15,722 Capital expenditures 6,245 6,307 11,205
13,931
Preclinical Services Net sales $ 124,964 $
142,477 $ 250,104 $ 282,513 Gross margin 29,018 43,257 54,656
83,164 Gross margin as a % of net sales 23.2 % 30.4 % 21.9 % 29.4 %
Operating income 4,728 16,336 4,465 26,882 Operating income as a %
of net sales 3.8 % 11.5 % 1.8 % 9.5 % Depreciation and amortization
14,778 14,851 29,319 29,148 Capital expenditures 2,187 14,130 6,520
31,131
Unallocated Corporate Overhead $
(23,782 ) $ (16,568 ) $ (44,001 ) $ (34,665 )
Total Net sales $ 292,104 $ 308,159 $ 589,449 $ 609,685
Gross margin 100,364 114,463 200,281 222,683 Gross margin as a % of
net sales 34.4 % 37.1 % 34.0 % 36.5 % Operating income 28,204
50,662 57,706 90,555 Operating income as a % of net sales 9.7 %
16.4 % 9.8 % 14.9 % Depreciation and amortization 23,589 22,900
47,851 44,870 Capital expenditures 8,432 20,437 17,725 45,062
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP TO NON-GAAP SELECTED BUSINESS
SEGMENT INFORMATION (UNAUDITED) (1) (dollars in
thousands)
Three Months Ended
Six Months Ended
June 26,2010
June 27,2009
June 26,2010
June 27,2009
Research Models and Services Net sales $ 167,140 $ 165,682 $
339,345 $ 327,172 Operating income 47,258 50,894 97,242 98,338
Operating income as a % of net sales 28.3 % 30.7 % 28.7 % 30.1 %
Add back: Amortization related to acquisitions 1,324 1,745 3,724
2,632 Severance
-
139 -
2,848 Operating income, excluding specified
charges (Non-GAAP) $ 48,582 $ 52,778 $ 100,966 $ 103,818 Non-GAAP
operating income as a % of net sales 29.1 % 31.9 % 29.8 % 31.7 %
Preclinical Services Net sales $ 124,964 $ 142,477 $
250,104 $ 282,513 Operating income 4,728 16,336 4,465 26,882
Operating income as a % of net sales 3.8 % 11.5 % 1.8 % 9.5 % Add
back: Amortization related to acquisitions 4,710 5,474 9,483 10,735
Severance 2,118 1,535 4,774 4,311 Impairment and other charges
(2) (41 ) 85 945 1,612 Operating losses for PCS Arkansas,
PCS Massachusetts & Phase 1 Scotland
3,538
1,139 7,009
2,682 Operating income, excluding
specified charges (Non-GAAP) $ 15,053 $ 24,569 $ 26,676 $ 46,222
Non-GAAP operating income as a % of net sales 12.0 % 17.2 % 10.7 %
16.4 %
Unallocated Corporate Overhead $
(23,782 ) $ (16,568 ) $ (44,001 ) $ (34,665 ) Add back: Severance
25 5 41 1,653 Impairment and other charges
(2) - 86 - 183
Costs associated with the evaluation of acquisitions 7,280 410
7,397 639 Convertible debt accounting
(3)
54 53
107 97 Unallocated
corporate overhead, excluding specified charges (Non-GAAP) $
(16,423 ) $ (16,014 ) $ (36,456 ) $ (32,093 )
Total Net sales $ 292,104 $ 308,159 $ 589,449 $ 609,685
Operating income 28,204 50,662 57,706 90,555 Operating income as a
% of net sales 9.7 % 16.4 % 9.8 % 14.9 % Add back: Amortization
related to acquisitions 6,034 7,219 13,207 13,367 Severance 2,143
1,679 4,815 8,812 Impairment and other charges
(2) (41 ) 171
945 1,795 Operating losses for PCS Arkansas, PCS Massachusetts
& Phase 1 Scotland 3,538 1,139 7,009 2,682 Costs associated
with the evaluation of acquisitions 7,280 410 7,397 639 Convertible
debt accounting
(3) 54
53 107
97 Operating income, excluding specified
charges (Non-GAAP) $ 47,212 $ 61,333 $ 91,186 $ 117,947 Non-GAAP
operating income as a % of net sales 16.2 % 19.9 % 15.5 % 19.3 %
(1) Charles River management believes
that supplementary non-GAAP financial measures provide useful
information to allow investors to gain a meaningful understanding
of our core operating results and future prospects, without the
effect of one-time charges and other items which are outside our
normal operations, consistent with the manner in which management
measures and forecasts the Company’s performance. The supplementary
non-GAAP financial measures included are not meant to be considered
superior to, or a substitute for results of operations prepared in
accordance with GAAP. The Company intends to continue to assess the
potential value of reporting non-GAAP results consistent with
applicable rules, regulations and guidance.
(2) For
the three months ended June 27, 2009, these items were related
primarily to costs associated with the Company’s divestiture of its
clinical Phase I business in Scotland on May 15, 2009. For the six
months ended June 26, 2010, these items were related primarily to
an asset impairment associated with the Company’s planned
disposition of its PCS facility in Arkansas. For the six months
ended June 27, 2009, these items were related primarily to an asset
impairment charge and costs associated with the Company’s
divestiture of its clinical Phase I business in Scotland and
additional miscellaneous expenses.
(3) This item
includes the impact of convertible debt accounting adopted at the
beginning of 2009, which increased depreciation expense.
CHARLES
RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF
GAAP EARNINGS TO NON-GAAP EARNINGS (1) (dollars in
thousands, except for per share data)
Three Months Ended
Six Months Ended
June 26,2010
June 27,2009
June 26,2010
June 27,2009
Net income attributable to common shareholders $ 14,454 $
34,154 $ 31,836 $ 59,559 Add back: Amortization related to
acquisitions 6,034 7,219 13,207 13,367 Severance 2,143 1,679 4,815
8,812 Impairment and other charges
(2) (41 ) 171 945 1,795
Operating losses for PCS Arkansas, PCS Massachusetts & Phase 1
Scotland 3,538 1,139 7,009 2,682 Costs associated with the
evaluation of acquisitions 8,313 410 8,430 639 Convertible debt
accounting, net
(3) 3,166 2,688 6,282 5,085 Tax expense from
repatriation 2,690 - 2,690 - Tax effect
(8,182
) (4,331 )
(13,760 ) (10,620
) Net income, excluding specified charges (Non-GAAP)
$ 32,115 $
43,129 $ 61,454
$ 81,319 Weighted
average shares outstanding - Basic 65,289,617 65,046,023 65,381,634
65,467,929 Effect of dilutive securities: Stock options and
contingently issued restricted stock 584,667 173,182 635,484
144,342 Warrants
-
3,293 -
3,227 Weighted average shares outstanding -
Diluted
65,874,284
65,222,498 66,017,118
65,615,498 Basic earnings
per share $ 0.22 $ 0.53 $ 0.49 $ 0.91 Diluted earnings per share $
0.22 $ 0.52 $ 0.48 $ 0.91 Basic earnings per share,
excluding specified charges (Non-GAAP) $ 0.49 $ 0.66 $ 0.94 $ 1.24
Diluted earnings per share, excluding specified charges (Non-GAAP)
$ 0.49 $ 0.66 $ 0.93 $ 1.24
(1) Charles River
management believes that supplementary non-GAAP financial measures
provide useful information to allow investors to gain a meaningful
understanding of our core operating results and future prospects,
without the effect of one-time charges and other items which are
outside our normal operations, consistent with the manner in which
management measures and forecasts the Company’s performance. The
supplementary non-GAAP financial measures included are not meant to
be considered superior to, or a substitute for results of
operations prepared in accordance with GAAP. The Company intends to
continue to assess the potential value of reporting non-GAAP
results consistent with applicable rules, regulations and guidance.
(2) For the three months ended June 27, 2009, these
items were related primarily to costs associated with the Company’s
divestiture of its clinical Phase I business in Scotland on May 15,
2009. For the six months ended June 26, 2010, these items were
related primarily to an asset impairment associated with the
Company’s planned disposition of its PCS facility in Arkansas. For
the six months ended June 27, 2009, these items were related
primarily to an asset impairment charge and costs associated with
the Company’s divestiture of its clinical Phase I business in
Scotland and additional miscellaneous expenses.
(3)
For the three and six months ended June 26, 2010, this includes the
impact of convertible debt accounting adopted at the beginning of
2009, which increased interest expense by $3,113 and $6,175 and
depreciation expense by $54 and $107, respectively. For the three
and six months ended June 27, 2009, this item includes the impact
of convertible debt accounting which increased interest expense by
$2,906 and $5,766, capitalized interest by $271 and $778 and
depreciation expense by $53 and $97, respectively.
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From May 2024 to Jun 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Jun 2023 to Jun 2024